JP2019076108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019076108A5 JP2019076108A5 JP2019006594A JP2019006594A JP2019076108A5 JP 2019076108 A5 JP2019076108 A5 JP 2019076108A5 JP 2019006594 A JP2019006594 A JP 2019006594A JP 2019006594 A JP2019006594 A JP 2019006594A JP 2019076108 A5 JP2019076108 A5 JP 2019076108A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- chain variable
- light chain
- variable region
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100019706 IGKV2-29 Human genes 0.000 claims 8
- 101710024481 IGKV2-29 Proteins 0.000 claims 8
- 102000018358 Immunoglobulins Human genes 0.000 claims 7
- 108060003951 Immunoglobulins Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 210000004602 germ cell Anatomy 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 2
- 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 claims 2
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 101710009640 IGKV1D-8 Proteins 0.000 claims 1
- 101710009635 IGKV2D-26 Proteins 0.000 claims 1
- 101710024987 IGKV3-20 Proteins 0.000 claims 1
- 101710009651 IGKV3D-15 Proteins 0.000 claims 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000000392 somatic Effects 0.000 claims 1
Claims (16)
- 目的の抗原に結合する抗体を作製する方法であって、
(a)遺伝子改変マウスを目的の抗原で免疫化するステップであって、
該遺伝子改変マウスが、その生殖系列ゲノムにおいて、ヒトVκ遺伝子セグメントおよびヒトJκ遺伝子セグメントを含む単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列についてホモ接合またはヘテロ接合であり、
該遺伝子改変マウスのB細胞によって発現されるすべての免疫グロブリンκ軽鎖が、該単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列またはその体細胞超変異バージョンから発現される免疫グロブリンκ軽鎖可変ドメインを含み、該遺伝子改変マウスは、再構成して内因性免疫グロブリン軽鎖可変領域配列を形成することができる内因性免疫グロブリンVκおよび/またはJκ遺伝子セグメントを欠いており、
該遺伝子改変マウスの生殖系列ゲノムは、ネズミ重鎖定常領域に作動可能に連結された、1または複数の再構成されていないヒトV H 遺伝子セグメント、1または複数の再構成されていないヒトD H 遺伝子セグメント、および、1または複数の再構成されていないヒトJ H 遺伝子セグメントを含む、
ステップと;
(b)該遺伝子改変マウスから、該目的の抗原に特異的に結合する抗体を発現するB細胞を得るステップと;
(c)該目的の抗原に特異的に結合する該抗体のヒト重鎖可変ドメインのアミノ酸配列を決定するか、または、該目的の抗原に特異的に結合する該抗体のヒト重鎖可変ドメインをコードするヌクレオチド配列を決定するステップと;
(d)該アミノ酸配列または該ヌクレオチド配列を用いて該目的の抗原に結合する抗体を生成するステップと
を含む、方法。 - 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列がVκ1−39/Jκ配列である、請求項1に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列がVκ1−39/Jκ5配列である、請求項2に記載の方法。
- 前記Vκ1−39/Jκ5配列が前記遺伝子改変マウスの生殖系列ゲノム中の操作された遺伝子座内に位置し、該操作された遺伝子座が配列番号1に示されるヌクレオチド配列を有する、請求項3に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列がVκ3−20/Jκ配列である、請求項1に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列がVκ3−20/Jκ1配列である、請求項5に記載の方法。
- 前記Vκ3−20/Jκ1配列が前記遺伝子改変マウスの生殖系列ゲノム中の操作された遺伝子座内に位置し、該操作された遺伝子座が配列番号11に示されるヌクレオチド配列を有する、請求項6に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列が、内因性マウスκ免疫グロブリン軽鎖可変領域遺伝子座において、前記遺伝子改変マウスの生殖系列ゲノム中に挿入されている、請求項1に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列が、すべての機能的な内因性マウスκ免疫グロブリン軽鎖可変領域遺伝子セグメントを置換するように、生殖系列ゲノムに位置する、請求項1に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列が、ネズミCκ配列に作動可能に連結される、請求項1に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列が、マウスCκ配列に作動可能に連結される、請求項1に記載の方法。
- 前記単一の再構成されたヒト免疫グロブリンκ軽鎖可変領域配列が、前記内因性マウスCκに作動可能に連結される、請求項8に記載の方法。
- 前記1または複数の再構成されていないヒトV H 遺伝子セグメントが、V H 1−2、V H 1−8、V H 1−24、V H 2−5、V H 3−7、V H 3−9、V H 3−11、V H 3−13、V H 3−15、V H 3−20、V H 3−23、V H 3−30、V H 3−33、V H 3−48、V H 4−31、V H 4−39、V H 4−59、V H 5−51、V H 6−1またはその組合せを含む、請求項1に記載の方法。
- 前記1または複数の再構成されていないヒトD遺伝子セグメントが、D1−7、D1−26、D3−3、D3−10、D3−16、D3−22、D5−5、D5−12、D6−6、D6−13、D7−27またはその組合せを含む、請求項1に記載の方法。
- 前記ネズミ重鎖定常領域がマウス重鎖定常領域である、請求項1に記載の方法。
- 前記マウス重鎖定常領域が内因性マウス重鎖定常領域である、請求項15に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020027029A JP6960005B2 (ja) | 2010-02-08 | 2020-02-20 | 共通の軽鎖のマウス |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30228210P | 2010-02-08 | 2010-02-08 | |
US61/302,282 | 2010-02-08 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017102567A Division JP6470789B2 (ja) | 2010-02-08 | 2017-05-24 | 共通の軽鎖のマウス |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020027029A Division JP6960005B2 (ja) | 2010-02-08 | 2020-02-20 | 共通の軽鎖のマウス |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019076108A JP2019076108A (ja) | 2019-05-23 |
JP2019076108A5 true JP2019076108A5 (ja) | 2019-06-27 |
JP6666483B2 JP6666483B2 (ja) | 2020-03-13 |
Family
ID=43663643
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012552144A Active JP5955781B2 (ja) | 2010-02-08 | 2011-02-08 | 共通の軽鎖のマウス |
JP2015133610A Active JP6215264B2 (ja) | 2010-02-08 | 2015-07-02 | 共通の軽鎖のマウス |
JP2017102567A Active JP6470789B2 (ja) | 2010-02-08 | 2017-05-24 | 共通の軽鎖のマウス |
JP2018088350A Pending JP2018138047A (ja) | 2010-02-08 | 2018-05-01 | 共通の軽鎖のマウス |
JP2019006594A Active JP6666483B2 (ja) | 2010-02-08 | 2019-01-18 | 共通の軽鎖のマウス |
JP2020027029A Active JP6960005B2 (ja) | 2010-02-08 | 2020-02-20 | 共通の軽鎖のマウス |
JP2021166030A Active JP7233504B2 (ja) | 2010-02-08 | 2021-10-08 | 共通の軽鎖のマウス |
JP2023025117A Active JP7538907B2 (ja) | 2010-02-08 | 2023-02-21 | 共通の軽鎖のマウス |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012552144A Active JP5955781B2 (ja) | 2010-02-08 | 2011-02-08 | 共通の軽鎖のマウス |
JP2015133610A Active JP6215264B2 (ja) | 2010-02-08 | 2015-07-02 | 共通の軽鎖のマウス |
JP2017102567A Active JP6470789B2 (ja) | 2010-02-08 | 2017-05-24 | 共通の軽鎖のマウス |
JP2018088350A Pending JP2018138047A (ja) | 2010-02-08 | 2018-05-01 | 共通の軽鎖のマウス |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020027029A Active JP6960005B2 (ja) | 2010-02-08 | 2020-02-20 | 共通の軽鎖のマウス |
JP2021166030A Active JP7233504B2 (ja) | 2010-02-08 | 2021-10-08 | 共通の軽鎖のマウス |
JP2023025117A Active JP7538907B2 (ja) | 2010-02-08 | 2023-02-21 | 共通の軽鎖のマウス |
Country Status (30)
Country | Link |
---|---|
US (5) | US10143186B2 (ja) |
EP (4) | EP2505654B2 (ja) |
JP (8) | JP5955781B2 (ja) |
KR (5) | KR101829691B1 (ja) |
CN (2) | CN102791866B (ja) |
AU (1) | AU2011213585B2 (ja) |
BR (2) | BR122014002928A2 (ja) |
CA (1) | CA2789154C (ja) |
CY (2) | CY1118241T1 (ja) |
DK (3) | DK2505654T4 (ja) |
ES (3) | ES2728942T3 (ja) |
HK (2) | HK1231505A1 (ja) |
HR (3) | HRP20151188T4 (ja) |
HU (3) | HUE026229T2 (ja) |
IL (3) | IL221265B (ja) |
LT (2) | LT3095871T (ja) |
ME (2) | ME02288B (ja) |
MX (3) | MX2012009168A (ja) |
MY (1) | MY166529A (ja) |
NZ (4) | NZ619512A (ja) |
PL (3) | PL2505654T5 (ja) |
PT (3) | PT3095871T (ja) |
RS (3) | RS59001B1 (ja) |
RU (2) | RU2571205C2 (ja) |
SG (4) | SG10201913463QA (ja) |
SI (3) | SI3095871T1 (ja) |
SM (2) | SMT201500283B (ja) |
TR (1) | TR201906650T4 (ja) |
WO (1) | WO2011097603A1 (ja) |
ZA (1) | ZA201205944B (ja) |
Families Citing this family (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
PE20081216A1 (es) | 2006-09-01 | 2008-09-04 | Therapeutic Human Polyclonals Inc | Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos |
DK2147594T3 (da) * | 2008-06-27 | 2014-02-10 | Merus B V | Antistofproducerende ikke-humane pattedyr |
JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
DK2421357T3 (da) | 2009-07-08 | 2013-04-15 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
ES2728942T3 (es) | 2010-02-08 | 2019-10-29 | Regeneron Pharma | Cadena ligera común de ratón |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
HUE044001T2 (hu) * | 2010-06-22 | 2019-09-30 | Regeneron Pharma | Humán variábilis régiót tartalmazó immunglobulin hibrid könnyûláncot expresszáló egerek |
MX363084B (es) | 2010-08-02 | 2019-03-07 | Regeneron Pharma | Ratones que producen proteinas de union que comprenden dominios vl. |
WO2012071592A2 (en) * | 2010-11-27 | 2012-05-31 | James Zhu | A humanized transgenic animal |
MY172713A (en) | 2011-02-25 | 2019-12-11 | Regeneron Pharma | Adam6 mice |
BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
KR101572338B1 (ko) | 2011-02-28 | 2015-11-26 | 에프. 호프만-라 로슈 아게 | 1가 항원 결합 단백질 |
NZ781020A (en) | 2011-08-05 | 2023-01-27 | Regeneron Pharma | Humanized universal light chain mice |
DK3311661T3 (da) | 2011-09-19 | 2022-07-11 | Kymab Ltd | Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer |
EP2758534B1 (en) * | 2011-09-19 | 2020-04-29 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
GB2495083A (en) * | 2011-09-26 | 2013-04-03 | Kymab Ltd | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates |
CA2791109C (en) * | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
RS55822B1 (sr) * | 2011-09-30 | 2017-08-31 | Dana-Farber Cancer Institute Inc | Terapijski peptidi |
CN108200885B (zh) | 2011-10-17 | 2021-12-14 | 瑞泽恩制药公司 | 受限制的免疫球蛋白重链基因座 |
US20140283153A1 (en) | 2011-10-28 | 2014-09-18 | Trianni, Inc. | Transgenic animals and methods of use |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
PL2793567T3 (pl) | 2011-12-20 | 2019-09-30 | Regeneron Pharmaceuticals, Inc. | Myszy z humanizowanym łańcuchem lekkim |
WO2013130981A1 (en) | 2012-03-02 | 2013-09-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to clostridium difficile toxins |
IN2014DN08163A (ja) * | 2012-03-06 | 2015-05-01 | Regeneron Pharma | |
EP2825035A1 (en) * | 2012-03-16 | 2015-01-21 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
EP3539374A1 (en) * | 2012-03-16 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing ph-sensitive immunoglobulin sequences |
AU2015227453B2 (en) * | 2012-03-16 | 2017-05-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing ph-sensitive immunoglobulin sequences |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
MY172730A (en) * | 2012-03-16 | 2019-12-11 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
PL2838917T3 (pl) | 2012-04-20 | 2019-12-31 | Merus N.V. | Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig |
AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
JP2015525071A (ja) * | 2012-06-05 | 2015-09-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法 |
RU2656155C2 (ru) | 2012-06-12 | 2018-05-31 | Регенерон Фармасьютикалз, Инк. | Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
ES2692951T3 (es) | 2012-09-27 | 2018-12-05 | Merus N.V. | Anticuerpos IgG biespecíficos como acopladores de células T |
SI2943511T1 (sl) | 2013-01-14 | 2020-01-31 | Xencor, Inc. | Novi heterodimerni proteini |
KR101764800B1 (ko) * | 2013-02-20 | 2017-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물 |
EP3543253B1 (en) * | 2013-02-20 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
US10154658B2 (en) * | 2013-02-22 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
CA2903025A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
JP6529957B2 (ja) * | 2013-03-13 | 2019-06-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 限られた免疫グロブリン軽鎖レパートリーを発現するマウス |
WO2014160179A1 (en) * | 2013-03-13 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP2967012B1 (en) | 2013-03-14 | 2020-09-16 | Erasmus University Medical Center Rotterdam | Transgenic non-human mammal for antibody production |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
MY172430A (en) | 2013-04-29 | 2019-11-25 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US20150033372A1 (en) * | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
CA2922892C (en) | 2013-09-18 | 2022-06-14 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
BR112016006502A2 (pt) | 2013-09-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
EP3842455A1 (en) | 2014-01-15 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with improved protein a-binding |
WO2015107026A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
EP3110846B1 (en) | 2014-02-28 | 2020-08-19 | Merus N.V. | Antibodies that bind egfr and erbb3 |
RS61129B1 (sr) | 2014-02-28 | 2020-12-31 | Merus Nv | Antitelo koje vezuje erbb-2 i erbb-3 |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
ES2872475T3 (es) * | 2014-03-21 | 2021-11-02 | Regeneron Pharma | Animales no humanos que producen proteínas de unión de dominio único |
AU2015231025A1 (en) | 2014-03-21 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
MX365658B (es) * | 2014-05-13 | 2019-06-10 | Univ Pennsylvania | Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos. |
HUE047385T2 (hu) | 2014-06-06 | 2020-04-28 | Bristol Myers Squibb Co | Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai |
CA2959428A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
JP2017531642A (ja) | 2014-10-03 | 2017-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | エボラ糖タンパク質に結合する抗体およびその使用 |
WO2016071377A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
KR20230125855A (ko) | 2014-11-21 | 2023-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73에 대항한 항체 및 그의 용도 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
ES2886523T3 (es) | 2014-11-26 | 2021-12-20 | Xencor Inc | Anticuerpos heterodiméricos que se unen a CD3 y CD20 |
KR20170084327A (ko) | 2014-11-26 | 2017-07-19 | 젠코어 인코포레이티드 | Cd3 및 cd38에 결합하는 이형이량체 항체 |
CA2971542A1 (en) | 2014-12-19 | 2016-06-23 | Regenesance B.V. | Antibodies that bind human c6 and uses thereof |
TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
PE20171244A1 (es) | 2014-12-23 | 2017-08-24 | Bristol Myers Squibb Co | Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmunorreceptor (tigit) |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
CN108137687B (zh) | 2015-05-29 | 2021-10-29 | 百时美施贵宝公司 | 抗ox40抗体及其用途 |
CA2990015A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
AU2016289480C1 (en) | 2015-07-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
TR201816055T4 (tr) | 2015-07-10 | 2018-11-21 | Merus Nv | İnsan CD3 bağlayıcı antikoru. |
JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
KR20180050412A (ko) | 2015-09-23 | 2018-05-14 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
BR112018008068A2 (pt) | 2015-10-23 | 2018-11-13 | Merus N.V. | moléculas de ligação que inibem o crescimento do câncer |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
RS64588B1 (sr) | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera |
SG10201914034WA (en) | 2016-01-13 | 2020-03-30 | Regeneron Pharma | Rodents having an engineered heavy chain diversity region |
SG11201807677YA (en) | 2016-03-04 | 2018-10-30 | Univ Rockefeller | Antibodies to cd40 with enhanced agonist activity |
SG10201913033UA (en) | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
MX2018013072A (es) | 2016-05-09 | 2019-03-21 | Squibb Bristol Myers Co | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. |
TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
US20170332610A1 (en) * | 2016-05-20 | 2017-11-23 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
CN116458475A (zh) | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
KR20190053835A (ko) * | 2016-06-21 | 2019-05-20 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
EP4050032A1 (en) | 2016-06-28 | 2022-08-31 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
MY200602A (en) | 2016-07-14 | 2024-01-04 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
PL3504233T3 (pl) | 2016-08-26 | 2024-06-24 | Sanofi | Wielospecyficzne przeciwciała ułatwiające selektywne parowanie łańcuchów lekkich |
WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
EA201990781A9 (ru) | 2016-09-23 | 2019-11-27 | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
SI3515487T1 (sl) | 2016-09-23 | 2023-09-29 | Regeneron Pharmaceuticals, Inc. | Bispecifična protitelesa proti-MUC16-CD3 in konjugati zdravil proti-MUC16 |
PE20191469A1 (es) | 2016-10-13 | 2019-10-16 | Massachusetts Inst Technology | Anticuerpos que se unen a la proteina de envoltura el virus zika y usos de los mismos |
MX2019009565A (es) | 2017-02-10 | 2020-02-24 | Regeneron Pharma | Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet. |
AU2018222743B2 (en) | 2017-02-17 | 2024-05-02 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
CN110382529B (zh) | 2017-03-02 | 2024-03-08 | 诺华股份有限公司 | 工程化的异源二聚体蛋白质 |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
SG11201912774RA (en) | 2017-06-20 | 2020-01-30 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
MX2019015563A (es) | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anticuerpos anti-bcma unicamente de cadena pesada. |
GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
TW201919582A (zh) | 2017-07-24 | 2019-06-01 | 美商再生元醫藥公司 | 穩定化之抗體組合物及其製法 |
CN118562014A (zh) | 2017-08-09 | 2024-08-30 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
MA50659A (fr) | 2017-09-29 | 2020-08-05 | Regeneron Pharma | Molécules bispécifiques de liaison à l'antigène se liant à un antigène cible de staphylococcus et à un composant de complément, et leurs utilisations |
WO2019118556A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
EA202091557A1 (ru) | 2017-12-22 | 2020-11-18 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
MX2020007772A (es) | 2018-01-26 | 2020-09-18 | Regeneron Pharma | Anticuerpos humanos contra hemaglutinina de influenza. |
BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
CN116874591A (zh) | 2018-03-24 | 2023-10-13 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途 |
CN112074538B (zh) | 2018-04-30 | 2024-10-18 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
SG11202011232VA (en) | 2018-05-17 | 2020-12-30 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
KR102617284B1 (ko) | 2018-06-14 | 2023-12-27 | 리제너론 파마슈티칼스 인코포레이티드 | 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물 |
BR112020025926A2 (pt) | 2018-06-21 | 2021-03-23 | Regeneron Pharmaceuticals, Inc. | anticorpos biespecíficos anti-psma x anti-cd28 e usos dos mesmos |
TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAx抗-CD3抗體及其用途 |
AU2019325565A1 (en) | 2018-08-23 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-Fc epsilon-R1 alpha (FceR1a) antibodies, bispecific antigen-binding molecules that bind FceR1a and CD3, and uses thereof |
MA53495A (fr) | 2018-08-31 | 2021-12-08 | Regeneron Pharma | Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20 |
JP7439076B2 (ja) | 2018-10-23 | 2024-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗npr1抗体およびその使用 |
US11274150B2 (en) | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
JP7463366B2 (ja) | 2018-11-20 | 2024-04-08 | タケダ ワクチン,インコーポレイテッド | 新規の抗ジカウイルス抗体及びその使用 |
JP2022512904A (ja) | 2018-11-21 | 2022-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗Staphylococcus抗体およびその使用 |
MX2021007497A (es) | 2018-12-19 | 2021-08-05 | Regeneron Pharma | Anticuerpos biespecificos anti-cd28 x anti-cd22 y usos de estos. |
SG11202105948TA (en) | 2018-12-19 | 2021-07-29 | Regeneron Pharma | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
EP3897117A1 (en) | 2018-12-21 | 2021-10-27 | Compass Therapeutics LLC | Transgenic mouse expressing common human light chain |
PE20212305A1 (es) | 2019-01-22 | 2021-12-10 | Bristol Myers Squibb Co | Anticuerpos contra subunidad alfa il-7r y usos de estos |
CA3125380A1 (en) | 2019-02-18 | 2020-08-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
WO2020172505A1 (en) | 2019-02-22 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
MX2021011500A (es) | 2019-03-22 | 2021-10-22 | Regeneron Pharma | Anticuerpos multiespecificos egfr x cd28. |
BR112021023683A2 (pt) | 2019-06-05 | 2022-02-01 | Regeneron Pharma | Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento |
CA3140075A1 (en) | 2019-06-11 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
US11905326B2 (en) | 2019-06-14 | 2024-02-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
MX2021015270A (es) | 2019-06-21 | 2022-01-18 | Regeneron Pharma | Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb. |
JP2022537019A (ja) | 2019-06-21 | 2022-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
JP2022543669A (ja) | 2019-08-08 | 2022-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規抗原結合分子フォーマット |
WO2021030680A1 (en) | 2019-08-15 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
GB201912008D0 (en) | 2019-08-21 | 2019-10-02 | Cambridge Entpr Ltd | Antibody |
KR20220088446A (ko) | 2019-10-28 | 2022-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 항-헤마글루티닌 항체 및 이의 사용 방법 |
KR20220110233A (ko) | 2019-12-02 | 2022-08-05 | 리제너론 파마슈티칼스 인코포레이티드 | 펩티드-mhc ii 단백질 작제물 및 그의 용도 |
KR20220110510A (ko) | 2019-12-06 | 2022-08-08 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-BCMA x 항-CD3 항체를 이용한 다발성 골수종의 치료 방법 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
US11945872B2 (en) | 2020-02-11 | 2024-04-02 | Regeneron Pharmaceuticals, Inc. | Anti-ACVR1 antibodies and uses thereof |
CA3176792C (en) | 2020-04-29 | 2024-06-18 | Katherine HARRIS | Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions |
KR20230009501A (ko) | 2020-05-12 | 2023-01-17 | 리제너론 파마슈티칼스 인코포레이티드 | 항-glp1r 길항제 항체 및 이의 이용 방법 |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2021244522A1 (en) * | 2020-06-02 | 2021-12-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
JP2023538891A (ja) * | 2020-08-19 | 2023-09-12 | ゼンコア インコーポレイテッド | 抗cd28組成物 |
EP4211155A1 (en) | 2020-09-11 | 2023-07-19 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
US11905332B2 (en) | 2020-09-18 | 2024-02-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof |
IL301702A (en) | 2020-10-22 | 2023-05-01 | Regeneron Pharma | Anti-FGFR2 antibodies and methods of using them |
CN118878693A (zh) | 2020-11-23 | 2024-11-01 | 康诺亚生物医药科技(成都)有限公司 | 一种双特异性抗体及其用途 |
CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
US20240317849A1 (en) | 2020-12-23 | 2024-09-26 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
EP4267608A1 (en) | 2020-12-23 | 2023-11-01 | Regeneron Pharmaceuticals, Inc. | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same |
AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
TW202400228A (zh) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | 減輕細胞激素釋放症候群的給藥方案 |
WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
AU2023271827A1 (en) | 2022-05-18 | 2024-12-05 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
WO2024015816A1 (en) | 2022-07-12 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
US20240150474A1 (en) | 2022-10-27 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification |
GB202217978D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
TW202430641A (zh) | 2023-01-18 | 2024-08-01 | 美商基利科學股份有限公司 | 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途 |
WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
WO2024173248A1 (en) | 2023-02-13 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Treatment of muscle related disorders with anti-human cacng1 antibodies |
US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE190355T1 (de) | 1988-09-06 | 2000-03-15 | Xoma Corp | Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) † | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
ATE140027T1 (de) | 1989-12-01 | 1996-07-15 | Pharming Bv | Herstellung rekombinanter polypeptide durch rinder und transgene methoden |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7067284B1 (en) * | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
EP1149898A2 (en) | 1993-12-23 | 2001-10-31 | Infigen, Inc. | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals |
DE69531148T2 (de) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | Bibliotheken aus polyklonalen antikörpern |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
CA2282722A1 (en) | 1997-03-06 | 1998-09-11 | Infigen, Inc. | Method of cloning animals |
DK0970126T3 (da) | 1997-04-14 | 2001-08-13 | Micromet Ag | Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf |
WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
WO1999018212A1 (fr) * | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain naturel |
AU760113C (en) | 1997-11-18 | 2004-04-22 | Pioneer Hi-Bred International, Inc. | Compositions and methods for genetic modification of plants |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DE60018171T3 (de) | 1999-04-15 | 2010-05-20 | Crucell Holland B.V. | Verwendung von adenovirus e1 protein kodierenden sequenzen, zur herstellung von rekombinanten proteinen in menschlichen zellen. |
EP1268832A4 (en) | 2000-02-29 | 2003-04-02 | Univ Auburn | PRODUCTION OF ANTIBODIES IN TRANSGENIC PLASTS |
RU2262511C2 (ru) | 2000-05-18 | 2005-10-20 | Джапан Тобакко, Инк. | Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение |
WO2002008409A2 (en) | 2000-07-21 | 2002-01-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Methods for the replacement, translocation and stacking of dna in eukaryotic genomes |
EA007958B1 (ru) | 2000-08-03 | 2007-02-27 | Терапеутик Хьюман Поликлоналз Инк. | ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ |
EP1184458A1 (en) | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) * | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
PL228041B1 (pl) | 2001-01-05 | 2018-02-28 | Amgen Fremont Inc | Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierajaca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana czasteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierze transgeniczne. |
US6961875B2 (en) | 2001-03-22 | 2005-11-01 | International Business Machines Corporation | Method and apparatus for capturing event traces for debug and analysis |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
JP2005522192A (ja) | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | マルチマータンパク質およびマルチマータンパク質を作製および使用する方法 |
DE50115587D1 (de) | 2001-10-01 | 2010-09-16 | Deutsches Krebsforsch | Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus |
US20060199204A1 (en) * | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
US20030108925A1 (en) * | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
DK1461442T3 (en) | 2001-11-30 | 2017-12-04 | Amgen Fremont Inc | Transgenic animals with human Ig lambda light chain genes |
GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
US20050095712A1 (en) | 2002-01-17 | 2005-05-05 | Alberto Martin | Mutations caused by activation-induced cytidine deaminase |
CN1617888A (zh) | 2002-01-18 | 2005-05-18 | 伊诺维奥埃斯 | 用于肌内给药的双特异性抗体dna的构建 |
EP1505148B1 (en) | 2002-04-26 | 2009-04-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for agonistic antibodies |
BR0311799A (pt) | 2002-06-14 | 2005-05-10 | Immunomedics Inc | Anticorpo monoclonal hpam4 |
CN101962408A (zh) | 2002-07-12 | 2011-02-02 | 杰斐逊·富特 | 超人源化抗体 |
NZ537277A (en) * | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
CL2003002461A1 (es) | 2002-11-27 | 2005-01-07 | Dow Chemical Company Agroscien | Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas. |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
JP4477579B2 (ja) | 2003-01-21 | 2010-06-09 | 中外製薬株式会社 | 抗体の軽鎖スクリーニング方法 |
WO2004067753A2 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
US20070009957A1 (en) | 2003-03-04 | 2007-01-11 | Alexion Pharmaceuticals, Inc. | Vectors used to create hybrid constant regions |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US20100069614A1 (en) * | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2532117C (en) | 2003-07-15 | 2012-07-10 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
US20050153392A1 (en) | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
CA2550551C (en) | 2004-01-16 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
CN1560081A (zh) | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链-κ轻链小鼠作为制备人源化单克隆抗体和应用 |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
JP2008517600A (ja) | 2004-10-22 | 2008-05-29 | セラピューティック ヒューマン ポリクローナルズ, インコーポレイテッド | ヒト以外のトランスジェニック動物における内因性免疫グロブリン発現の抑制 |
KR20070090890A (ko) * | 2004-10-22 | 2007-09-06 | 메디뮨 인코포레이티드 | Hmgb1에 대한 고 친화성 항체 및 이의 사용 방법 |
CA2604440A1 (en) | 2005-04-29 | 2006-11-09 | Inserm (Institut De La Sante Et De La Recherche Medicale) | Transgenic animals and methods of making recombinant antibodies |
BRPI0520212A2 (pt) | 2005-05-14 | 2009-08-18 | Univ Fudan | métodos de geração de um vertebrado não humano transgênico, e de uma célula de vertebrado recombinante, célula de vertebrado em cultura, e, ácido nucleico |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
JP2009518320A (ja) * | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
RU2435784C2 (ru) | 2006-01-25 | 2011-12-10 | Эрасмус Юниверсити Медикал Сентр Роттердам | Получение антител из одних тяжелых цепей в трансгенных животных |
US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
US7910798B2 (en) * | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
SI2041177T1 (sl) * | 2006-06-02 | 2012-03-30 | Regeneron Pharma | Visoko afinitetna protitelesa za humani IL receptor |
WO2008022391A1 (en) | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Method for producing antibodies |
ES2859825T3 (es) | 2006-10-02 | 2021-10-04 | Regeneron Pharma | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
WO2008112922A2 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
ATE522611T1 (de) | 2007-06-01 | 2011-09-15 | Omt Inc | Zusammensetzungen und verfahren zur hemmung engodener immunglobulingene und zur erzeugung transgener menschlicher idiotypischer antikörper |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
ITMI20071522A1 (it) * | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル.エル.シー. | Hco32およびhco27、ならびに関連実施例 |
CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ, エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
PT2222706E (pt) | 2007-12-14 | 2014-07-28 | Novo Nordisk As | Anticorpos contra nkg2d humano e utilizações dos mesmos |
EP3061770B8 (en) | 2008-01-07 | 2020-02-12 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
CA2721231C (en) | 2008-04-14 | 2015-10-06 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
US20110123527A1 (en) | 2008-05-23 | 2011-05-26 | Hiroaki Shizuya | Method of generating single vl domain antibodies in transgenic animals |
DK2147594T3 (da) | 2008-06-27 | 2014-02-10 | Merus B V | Antistofproducerende ikke-humane pattedyr |
US9346873B2 (en) | 2008-09-30 | 2016-05-24 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
JP5882058B2 (ja) | 2008-11-07 | 2016-03-09 | ファブラス エルエルシー | 組合せ抗体ライブラリー及びその使用 |
JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
US20110305692A1 (en) | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Antigen-binding contructs |
US8808136B2 (en) | 2009-05-07 | 2014-08-19 | Volvo Construction Equipment Ab | Working machine and a method for operating a working machine |
JP5804521B2 (ja) | 2009-05-29 | 2015-11-04 | モルフォシス・アー・ゲー | コレクション及びその使用方法 |
MY192182A (en) † | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
DK2421357T3 (da) | 2009-07-08 | 2013-04-15 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
CN102803488A (zh) | 2009-11-17 | 2012-11-28 | 协和发酵麒麟株式会社 | 人类人工染色体载体 |
PL2509409T3 (pl) | 2009-12-10 | 2017-02-28 | Regeneron Pharmaceuticals, Inc. | Myszy wytwarzające przeciwciała ciężkołańcuchowe |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130185821A1 (en) * | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
ES2728942T3 (es) * | 2010-02-08 | 2019-10-29 | Regeneron Pharma | Cadena ligera común de ratón |
JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
AU2011266843C9 (en) | 2010-06-17 | 2018-03-01 | Kymab Limited | Animal models and therapeutic molecules |
HUE044001T2 (hu) | 2010-06-22 | 2019-09-30 | Regeneron Pharma | Humán variábilis régiót tartalmazó immunglobulin hibrid könnyûláncot expresszáló egerek |
MX363084B (es) | 2010-08-02 | 2019-03-07 | Regeneron Pharma | Ratones que producen proteinas de union que comprenden dominios vl. |
MY172713A (en) | 2011-02-25 | 2019-12-11 | Regeneron Pharma | Adam6 mice |
NZ781020A (en) | 2011-08-05 | 2023-01-27 | Regeneron Pharma | Humanized universal light chain mice |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
CN108200885B (zh) | 2011-10-17 | 2021-12-14 | 瑞泽恩制药公司 | 受限制的免疫球蛋白重链基因座 |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
IN2014DN08163A (ja) | 2012-03-06 | 2015-05-01 | Regeneron Pharma | |
PL2838917T3 (pl) | 2012-04-20 | 2019-12-31 | Merus N.V. | Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig |
JP2015525071A (ja) | 2012-06-05 | 2015-09-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法 |
WO2014160179A1 (en) | 2013-03-13 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
JP6529957B2 (ja) | 2013-03-13 | 2019-06-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 限られた免疫グロブリン軽鎖レパートリーを発現するマウス |
-
2011
- 2011-02-08 ES ES16178223T patent/ES2728942T3/es active Active
- 2011-02-08 SG SG10201913463QA patent/SG10201913463QA/en unknown
- 2011-02-08 HU HUE11703799A patent/HUE026229T2/en unknown
- 2011-02-08 WO PCT/US2011/023971 patent/WO2011097603A1/en active Application Filing
- 2011-02-08 NZ NZ619512A patent/NZ619512A/en unknown
- 2011-02-08 SI SI201131725T patent/SI3095871T1/sl unknown
- 2011-02-08 PT PT16178223T patent/PT3095871T/pt unknown
- 2011-02-08 KR KR1020127021534A patent/KR101829691B1/ko active IP Right Grant
- 2011-02-08 SG SG10201500821UA patent/SG10201500821UA/en unknown
- 2011-02-08 KR KR1020187003853A patent/KR101995735B1/ko active IP Right Grant
- 2011-02-08 CA CA2789154A patent/CA2789154C/en active Active
- 2011-02-08 ES ES12173456T patent/ES2603559T5/es active Active
- 2011-02-08 PL PL12173456T patent/PL2505654T5/pl unknown
- 2011-02-08 EP EP12173456.0A patent/EP2505654B2/en active Active
- 2011-02-08 NZ NZ719253A patent/NZ719253A/en unknown
- 2011-02-08 DK DK12173456.0T patent/DK2505654T4/da active
- 2011-02-08 PT PT121734560T patent/PT2505654T/pt unknown
- 2011-02-08 PT PT117037994T patent/PT2501817E/pt unknown
- 2011-02-08 BR BR122014002928A patent/BR122014002928A2/pt not_active Application Discontinuation
- 2011-02-08 MX MX2012009168A patent/MX2012009168A/es active IP Right Grant
- 2011-02-08 SG SG2012057485A patent/SG183149A1/en unknown
- 2011-02-08 HU HUE12173456A patent/HUE029785T2/en unknown
- 2011-02-08 DK DK16178223.0T patent/DK3095871T3/da active
- 2011-02-08 MX MX2015007651A patent/MX350983B/es unknown
- 2011-02-08 CN CN201180013714.0A patent/CN102791866B/zh active Active
- 2011-02-08 RS RS20190849A patent/RS59001B1/sr unknown
- 2011-02-08 SI SI201131024T patent/SI2505654T2/sl unknown
- 2011-02-08 US US13/022,759 patent/US10143186B2/en active Active
- 2011-02-08 KR KR1020207014664A patent/KR102283195B1/ko active IP Right Grant
- 2011-02-08 DK DK11703799.4T patent/DK2501817T4/da active
- 2011-02-08 KR KR1020197018579A patent/KR102116296B1/ko active IP Right Grant
- 2011-02-08 JP JP2012552144A patent/JP5955781B2/ja active Active
- 2011-02-08 ME MEP-2015-197A patent/ME02288B/me unknown
- 2011-02-08 EP EP19157278.3A patent/EP3540066A1/en active Pending
- 2011-02-08 ES ES11703799T patent/ES2547142T5/es active Active
- 2011-02-08 SI SI201130642T patent/SI2501817T2/sl unknown
- 2011-02-08 RU RU2012138431/10A patent/RU2571205C2/ru active
- 2011-02-08 RU RU2015147726A patent/RU2724663C2/ru active
- 2011-02-08 NZ NZ631363A patent/NZ631363A/en unknown
- 2011-02-08 RS RS20150772A patent/RS54367B2/sr unknown
- 2011-02-08 RS RS20161014A patent/RS55315B2/sr unknown
- 2011-02-08 PL PL16178223T patent/PL3095871T3/pl unknown
- 2011-02-08 EP EP11703799.4A patent/EP2501817B2/en active Active
- 2011-02-08 HU HUE16178223A patent/HUE045591T2/hu unknown
- 2011-02-08 NZ NZ601679A patent/NZ601679A/en unknown
- 2011-02-08 LT LTEP16178223.0T patent/LT3095871T/lt unknown
- 2011-02-08 BR BR112012019887-4A patent/BR112012019887B1/pt active IP Right Grant
- 2011-02-08 CN CN201510354745.2A patent/CN105010238B/zh active Active
- 2011-02-08 PL PL11703799T patent/PL2501817T5/pl unknown
- 2011-02-08 KR KR1020217023446A patent/KR102432611B1/ko active IP Right Grant
- 2011-02-08 TR TR2019/06650T patent/TR201906650T4/tr unknown
- 2011-02-08 AU AU2011213585A patent/AU2011213585B2/en active Active
- 2011-02-08 ME MEP-2016-271A patent/ME02646B/me unknown
- 2011-02-08 LT LTEP12173456.0T patent/LT2505654T/lt unknown
- 2011-02-08 MY MYPI2012003497A patent/MY166529A/en unknown
- 2011-02-08 EP EP16178223.0A patent/EP3095871B1/en active Active
-
2012
- 2012-03-06 US US13/412,936 patent/US20120192300A1/en not_active Abandoned
- 2012-08-02 IL IL221265A patent/IL221265B/en active IP Right Grant
- 2012-08-07 ZA ZA2012/05944A patent/ZA201205944B/en unknown
- 2012-08-08 MX MX2021000286A patent/MX2021000286A/es unknown
- 2012-10-17 HK HK17104973.4A patent/HK1231505A1/zh unknown
-
2013
- 2013-02-06 HK HK13101647.0A patent/HK1174358A1/zh unknown
- 2013-03-05 SG SG10201610294RA patent/SG10201610294RA/en unknown
- 2013-07-23 US US13/948,818 patent/US20130302836A1/en not_active Abandoned
-
2015
- 2015-07-02 JP JP2015133610A patent/JP6215264B2/ja active Active
- 2015-11-05 HR HRP20151188TT patent/HRP20151188T4/hr unknown
- 2015-11-19 SM SM201500283T patent/SMT201500283B/it unknown
-
2016
- 2016-11-17 CY CY20161101191T patent/CY1118241T1/el unknown
- 2016-11-22 HR HRP20161551TT patent/HRP20161551T4/hr unknown
- 2016-11-24 SM SM201600432T patent/SMT201600432B/it unknown
-
2017
- 2017-05-24 JP JP2017102567A patent/JP6470789B2/ja active Active
-
2018
- 2018-05-01 JP JP2018088350A patent/JP2018138047A/ja active Pending
- 2018-10-19 US US16/165,987 patent/US10986820B2/en active Active
-
2019
- 2019-01-18 JP JP2019006594A patent/JP6666483B2/ja active Active
- 2019-06-16 IL IL267362A patent/IL267362B/en unknown
- 2019-07-01 HR HRP20191191TT patent/HRP20191191T1/hr unknown
- 2019-07-05 CY CY20191100710T patent/CY1121794T1/el unknown
-
2020
- 2020-02-20 JP JP2020027029A patent/JP6960005B2/ja active Active
-
2021
- 2021-03-23 US US17/209,964 patent/US20210204531A1/en active Pending
- 2021-10-08 JP JP2021166030A patent/JP7233504B2/ja active Active
-
2022
- 2022-01-24 IL IL290085A patent/IL290085A/en unknown
-
2023
- 2023-02-21 JP JP2023025117A patent/JP7538907B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019076108A5 (ja) | ||
JP7538907B2 (ja) | 共通の軽鎖のマウス | |
JP5993102B2 (ja) | 修飾された免疫グロブリン重鎖配列を有する非ヒト動物 | |
IL264362A (en) | Non-human animals expressing immunoglobulin sequences are sensitive to ph | |
HUE027949T2 (en) | Nonhuman animals expressing common light chain antibodies | |
JP2015525071A5 (ja) | ||
JPWO2020247623A5 (ja) | ||
JP2023011882A5 (ja) | ||
JP2024156973A (ja) | 共通の軽鎖のマウス | |
AU2014200245B2 (en) | Common light chain mouse | |
AU2014233618B2 (en) | Mice that make heavy chain antibodies | |
RU2018126211A (ru) | Мыши с гуманизированной универсальной легкой цепью | |
AU2016203148A1 (en) | Common light chain mouse |